Pfizer Incorporated astounded the world on Wednesday, as the company announced that the late stage trial of their new breast cancer treatment, called Ibrance, was stopped, after the medicine succeeded to delay the disease’s progression in the patients treated with the wonder drug.


The analyst at J.P. Morgan, Chris Schott stated that he expects the demand for the treatment that has recently been approved to go through the roof, as the medicine has amazing potential. The predictions are that the Ibrance could rake a record breaking income of more than 5 billion US dollars per year.

The Paloma 3, the Phase 3 study of the medicine, was stopped as the independent data monitoring board established that the palbociclib, the other name for Ibrance, was positively proven to be effective on the patients suffering from disease in the advanced stage, previously receiving anti-estrogen treatment. The coming medical meeting will be the place where these historical data will be presented to the public.

The drug was given to the patients along with the with AstraZeneca Plc’s Faslodex, often used as an estrogen blocker. The patients using both drugs showed better results compared to the group that was only treated with Faslodex. The patients participating in the trial were diagnosed with an estrogen-receptor positive and human epidermal growth factor receptor 2-negative form of breast cancer.

The FDA (Food and Drug Administration) in the United States approved the Ibrance in February for patients diagnosed with that type of breast cancer, but only the patients who weren’t treated for advanced disease before.